- Volume 15 Issue 18
DOI QR Code
Number of Mediastinal Lymph Nodes as a Prognostic Factor in PN2 Non Small Cell Lung Cancer: A Single Centre Experience and Review of the Literature
- Takanen, Silvia (Department of Radiation Oncology, Azienda Policlinico Umberto I, "Sapienza" University of Rome) ;
- Bangrazi, Caterina (Department of Radiation Oncology, Azienda Policlinico Umberto I, "Sapienza" University of Rome) ;
- Graziano, Vanessa (Department of Radiation Oncology, Azienda Policlinico Umberto I, "Sapienza" University of Rome) ;
- Parisi, Alessandro (Department of Radiation Oncology, Azienda Policlinico Umberto I, "Sapienza" University of Rome) ;
- Resuli, Blerina (Department of Radiation Oncology, Azienda Policlinico Umberto I, "Sapienza" University of Rome) ;
- Simione, Luca (Department of Radiation Oncology, Azienda Policlinico Umberto I, "Sapienza" University of Rome) ;
- Caiazzo, Rossella (Department of Radiation Oncology, Azienda Policlinico Umberto I, "Sapienza" University of Rome) ;
- Raffetto, Nicola (Department of Radiation Oncology, Azienda Policlinico Umberto I, "Sapienza" University of Rome) ;
- Tombolini, Vincenzo (Department of Radiation Oncology, Azienda Policlinico Umberto I, "Sapienza" University of Rome)
- Published : 2014.10.11
Currently the most important prognostic factor in lung cancer is the stage. In the current lung TNM classification system, N category is defined exclusively by anatomic nodal location though, in other type of tumours, number of lymph nodes is confirmed to be a fundamental prognostic factor. Therefore we evaluated the number of mediastinal lymph nodes as a prognostic factor in locally advanced NSCLC after multimodality treatment, observing a significant effect of the number of lymph nodes in terms of OS (p<0.01) and DFS (p<0.001): patients with a low number of positive mediastinal nodes have a better prognosis.
- Bradley JD, Paulus R, Graham MV, et al, Radiation Therapy Oncology Group, (2005). Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer:promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. J Clin Oncol, 23, 3480-7. https://doi.org/10.1200/JCO.2005.12.120
- Bria E, Milella M, Sperduti I, et al, (2009). A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-smallcell lung cancer. Lung Cancer, 66, 365-71. https://doi.org/10.1016/j.lungcan.2009.02.024
- Detterbeck FC, Boffa DJ, Tanoue LT, (2009). The new lung cancer staging system. Chest, 136, 260-71. https://doi.org/10.1378/chest.08-0978
- Goldstraw P, (2009). The 7th Edition of TNM in Lung Cancer: What Now? J Thorac Oncol, 4, 671-673. https://doi.org/10.1097/JTO.0b013e31819e7814
- Doddoli C, D'Journo B, Le Pimpec-Barthes F, et al, (2005). Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies. Ann Thorac Surg, 80, 2032-40. https://doi.org/10.1016/j.athoracsur.2005.03.088
- End A. (2006). Diagnosis and treatment of lung cancer- nonsmall cell lung cancer, small cell lung cancer and carcinoids. Eur Surg, 38,45-53. https://doi.org/10.1007/s10353-006-0209-0
- Fukui T, Mori S, Yokoi K, et al, (2006). Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol, 1, 120-5. https://doi.org/10.1097/01243894-200602000-00004
- Kligerman S, Abbott G, (2010). A radiologic review of the new TNM classification for lung cancer. Am J Radiology, 194, 562-573.
- Lee CY, Byun CS, Lee JG, et al, (2012). The prognostic factors of resected non-small cell lung cancer with chest wall invasion. World J Surg Oncol, 10, 9. https://doi.org/10.1186/1477-7819-10-9
- Macia I, Ramos R, Moya J, et al, (2013). Survival of patients with non-small cell lung cancer according to lymph node disease: single pN1 vs multiple pN1 vs single unsuspected pN2. Ann Surg Oncol, 20, 2413-8. https://doi.org/10.1245/s10434-012-2865-6
- Mantovani C, Levra NG, Filippi AR, et al, (2012). Postoperative radiotherapy for patients with completely resecate pathologic N2 non-small cell lung cancer: a retrospective analysis. Clin Lung Cancer, 9, 1-6.
- Maximus S, Nguyen DV, Mu Y, et al, (2012). Size of stage IIIA primary lung cancers and survival: a Surveillance, Epidemiology and End Results Database analysis. Am Surg, 78, 1232-7.
- Moretti L, Yu DS, Chen H, et al (2009). Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. Oncologist, 14, 1106-15. https://doi.org/10.1634/theoncologist.2009-0130
- Nwogu CE, Groman A, Fahey D, et al, (2012). Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg, 93, 1614-9. https://doi.org/10.1016/j.athoracsur.2012.01.065
- Okamoto L, (2008). Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. Int J Clin Oncol, 13, 112-6. https://doi.org/10.1007/s10147-007-0754-y
- Osarogiagbon RU, (2012). Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM. J Thorac Dis, 4, 214-6.
- Penland SK, Socinski MA, (2004). Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation. Semin Radiat Oncol, 14, 326-34. https://doi.org/10.1016/j.semradonc.2004.07.002
- Saji H, Tsuboi M, Shimada Y, et al, (2013). A proposal for combination of total number and anatomical location of involved lymph nodes for nodal classification in non-small cell lung cancer. Chest, 143, 1618-25. https://doi.org/10.1378/chest.12-0750
- Saji H, Tsuboi M, Yoshida K, et al, (2011). Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer. J Thorac Oncol, 6, 1865-71. https://doi.org/10.1097/JTO.0b013e31822a35c3
- Wakelee HA, Stephenson P, Keller SM, et al, (2005). Eastern Cooperative Oncology Group, Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer, 48, 389-397. https://doi.org/10.1016/j.lungcan.2004.11.007
- Knocking Down Nucleolin Expression Enhances the Radiosensitivity of Non-Small Cell Lung Cancer by Influencing DNA-PKcs Activity vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3301
- Comparison of quick recovery outcome of inhalable doxorubicin and cisplatin in lung cancer patients: a randomized, double-blind, single-center trial vol.8, pp.5, 2018, https://doi.org/10.1007/s13346-018-0529-1